Topical Collection "Frontiers in Breast Cancer Diagnosis and Treatment"

A topical collection in Medicina (ISSN 1648-9144). This collection belongs to the section "Oncology".

Viewed by 3739

Editors

Dr. Tithi Biswas
E-Mail Website
Collection Editor
1. Department of Radiation Oncology, School of Medicine, Case Western Reserve University, Cleveland, OH, USA
2. University Hospitals Seidman Cancer Center, 11100 Euclid Avenue Cleveland, OH, USA
Interests: breast, esophageal and colorectal cancer; gastrointestinal cancers, general, and thoracic
Special Issues, Collections and Topics in MDPI journals

Topical Collection Information

Dear Colleagues,

Reducing breast cancer risk through targeted screening, treatment advances, and novel research efforts is the key focus of this Topical Collection on “Progress in Breast Cancer Diagnosis and Treatment”. We are also interested in manuscripts aimed at improving the quality of life of breast cancer patients and survivors. In this regard, research topics include, but are not limited to, lifestyle factors and habits such as nutrition, exercise, and weight control, as well as supportive care. 

Of particular interest to this Topical Collection is research pertaining to circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA). Such research may offer a less-expensive and non-invasive means for predicting disease severity and survival potential in breast cancer patients.  Submissions focusing on evolving therapies (e.g., atezolizumab, nab-paclitaxel, ipatasertib, capivasertib, and bicalutamide) also are welcome. 

Prof. Dr. Jimmy T. Efird
Dr. Tithi Biswas
Collection Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the collection website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • breast cancer
  • TNBC
  • ER-positive tumors
  • HER2-positive tumors
  • inflammatory breast cancer
  • novel therapies
  • breast cancer survival
  • health promotion
  • lifestyle behaviors and habits
  • epidemiology of breast cancer

Published Papers (3 papers)

2023

Jump to: 2022

Article
A Hypofractionated Radiotherapy Schedule with a Simultaneous Integrated Boost for Breast Cancer: Outcomes including Late Toxicity and Health Quality
Medicina 2023, 59(4), 675; https://doi.org/10.3390/medicina59040675 - 29 Mar 2023
Viewed by 625
Abstract
Introduction: This study aimed to evaluate the long-term adverse effects on the physical appearance and overall well-being of breast cancer patients who receive hypofractionated radiotherapy as whole breast and simultaneous integrated boost (SIB) treatment, utilizing intensive modulated radiotherapy (IMRT), volumetric modulated arc [...] Read more.
Introduction: This study aimed to evaluate the long-term adverse effects on the physical appearance and overall well-being of breast cancer patients who receive hypofractionated radiotherapy as whole breast and simultaneous integrated boost (SIB) treatment, utilizing intensive modulated radiotherapy (IMRT), volumetric modulated arc therapy (VMAT), or a hybrid therapy approach. Material/Methods: This investigation involved administering hypofractionated SIB-VMAT therapy to individuals diagnosed with early-stage breast cancer. Treatment was carried out over a three-week period in which a total dose of 48.06 Gy was given to the entire breast and 54 Gy was given to the tumor bed. Data on skin toxicity and cosmetic outcomes were analyzed both during the acute phase and during the three-month and five-year follow-up periods after treatment. Results: A total of 125 patients treated between December 2014 and December 2016 were included in the study. The data of these patients with at least 5 years of follow-up were analyzed. Conclusions: Considering these long-term results, hypofractionated SIB-VMAT can be considered a viable treatment choice, even for patients with unfavorable conditions. Full article

2022

Jump to: 2023

Review
Molecular Pathways Related to Sulforaphane as Adjuvant Treatment: A Nanomedicine Perspective in Breast Cancer
Medicina 2022, 58(10), 1377; https://doi.org/10.3390/medicina58101377 - 01 Oct 2022
Cited by 4 | Viewed by 1317
Abstract
Because cancer is a multifactorial disease, it is difficult to identify the specific agents responsible for the disease’s progression and development, but lifestyle and diet have been shown to play a significant role. Diverse natural compounds are demonstrating efficacy in the development of [...] Read more.
Because cancer is a multifactorial disease, it is difficult to identify the specific agents responsible for the disease’s progression and development, but lifestyle and diet have been shown to play a significant role. Diverse natural compounds are demonstrating efficacy in the development of novel cancer therapies, including sulforaphane (1-isothiocyanate-4-(methylsulfinyl)butane), a compound found in broccoli and other cruciferous vegetables that promotes key biological processes such as apoptosis, cell cycle arrest, autophagy, and suppression of key signalling pathways such as the PI3K/AKT/mTOR pathway in breast cancer cells. However, one of the primary challenges with sulforaphane treatment is its low solubility in water and oral bioavailability. As a consequence, several investigations were conducted using this component complexed in nanoparticles, which resulted in superior outcomes when combined with chemotherapy drugs. In this study, we discuss the properties and benefits of sulforaphane in cancer therapy, as well as its ability to form complexes with nanomolecules and chemotherapeutic agents that synergize the antitumour response in breast cancer cells. Full article
Show Figures

Figure 1

Editorial
On the Frontiers of Breast Cancer Diagnosis and Treatment: Current and Future Directions in a Rapidly Changing Field
Medicina 2022, 58(8), 1026; https://doi.org/10.3390/medicina58081026 - 31 Jul 2022
Viewed by 1080
Abstract
Breast cancer (BCa) represents a medically heterogeneous group of malignancies, with differing biological and genetic makeups [...] Full article
Back to TopTop